SDGR
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of 2.50 suggests a premium over book value despite lack of profitability.
- Price/Sales ratio of 3.56 is moderate for the sector
- Negative P/E ratio
- No Graham Number due to lack of earnings
Revenue growth is currently -1.20%, contradicting growth-stock valuations.
- High analyst target price ($21.38)
- Negative YoY revenue growth
- Poor earnings surprise track record
Long-term trend is aggressively bearish.
- Recent 1-week price bounce (+8.5%)
- 5-year return of -83%
- 1-year return of -52.1%
Strong balance sheet liquidity is the only offset to poor operational health.
- Low Debt/Equity (0.30)
- High Quick Ratio (2.64)
- Piotroski F-Score of 2/9
Company is in a growth/burn phase with no yield.
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SDGR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SDGR
Schrödinger, Inc.
Primary
|
-83.0% | -58.3% | -52.1% | -36.1% | +3.0% | +8.5% |
|
OPK
OPKO Health, Inc.
Peer
|
-72.8% | -20.8% | -18.1% | -22.4% | -0.8% | -0.8% |
|
FTRE
Fortrea Holdings Inc.
Peer
|
-68.8% | -68.8% | +45.4% | -12.7% | +4.8% | -0.7% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
QDEL
QuidelOrtho Corporation
Peer
|
-89.6% | -86.0% | -49.5% | -54.8% | -25.4% | -8.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SDGR
Schrödinger, Inc.
|
BEARISH | $911.0M | - | -26.3% | -40.4% | $12.34 | |
|
OPK
OPKO Health, Inc.
|
BEARISH | $905.89M | - | -17.1% | -37.2% | $1.18 | Compare |
|
FTRE
Fortrea Holdings Inc.
|
BEARISH | $877.03M | - | -102.4% | -36.2% | $9.38 | Compare |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
|
QDEL
QuidelOrtho Corporation
|
BEARISH | $865.32M | - | -46.1% | -41.5% | $12.71 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | HERMAN JENNY | Officer | Sale | 1,383 | $17,764 |
| 2026-03-05 | LORTON KENNETH PATRICK | Officer | Sale | 1,222 | $15,761 |
| 2026-03-05 | TRAN YVONNE KIM | Officer | Sale | 1,094 | $14,107 |
| 2026-03-05 | FRIESNER RICHARD A | Chief Executive Officer | Sale | 3,661 | $47,249 |
| 2026-03-05 | AKINSANYA-AKIWUMI KAREN OLUFUNMILYO | President | Sale | 1,366 | $17,625 |
| 2026-03-05 | JAIN RACHIT | Chief Financial Officer | Sale | 1,631 | $21,033 |
| 2026-03-04 | ABEL ROBERT LORNE | Officer | Sale | 1,300 | $16,653 |
| 2026-03-02 | HERMAN JENNY | Officer | Stock Award | 9,590 | - |
| 2026-03-02 | LORTON KENNETH PATRICK | Chief Technology Officer | Stock Award | 37,812 | - |
| 2026-03-02 | TRAN YVONNE KIM | Officer | Stock Award | 30,918 | - |
| 2026-03-02 | FRIESNER RICHARD A | Director | Option Exercise | 160,527 | $492,818 |
| 2026-03-02 | ABEL ROBERT LORNE | Officer | Stock Award | 37,812 | - |
| 2026-03-02 | RAMY SAMIR FARID PH.D. | Chief Executive Officer | Stock Award | 118,113 | - |
| 2026-03-02 | RAMY SAMIR FARID PH.D. | Chief Executive Officer | Sale | 5,560 | $66,151 |
| 2026-03-02 | AKINSANYA-AKIWUMI KAREN OLUFUNMILYO | President | Stock Award | 57,903 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
SDGR is subject to royalty and other financial obligations under license agreements with Columbia University and other licensors. The company faces significant risk if these agreements are terminated due to alleged breaches, which could delay the commercialization of software solutions and allow competitors to undermine its market position.
SDGR is subject to royalty and other obligations under license agreements with Columbia University and other licensors. The company faces material risks if these agreements are terminated due to breaches, which could delay the commercialization of software solutions and allow competitors to enter the market. Such outcomes could significantly impair the company's competitive position and financial condition.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SDGR from our newsroom.